Trial Profile
Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Corticosteroids
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms GvHD-ATO
- Sponsors Medsenic
- 12 Mar 2024 According to BioSenic Media Release, company announces the publication of an open-access article describing an optimized schedule for administration of oral arsenic trioxide (OATO) treatment for chronic graft-versus-host disease (cGvHD), based on an earlier post-hoc analysis of Phase 2 data. The schedule will play an important role in the protocol for BioSenic's forthcoming pivotal Phase 3 clinical trial.
- 27 Sep 2023 According to BioSenic Media Release, company erforms further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD. This analysis will be used to decide on the best oral ATO's posology for BioSenic's forthcoming phase 3 clinical trial.
- 27 Sep 2023 Post-hoc analysis results presented in a BioSenic Media Release.